Evorpacept for squamous cell carcinoma of head and neck

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 19 Dec 2020: Trial registered, NCT04675294
  2. 2 Apr 2021: Trial started, NCT04675294

The trials

NCT04675294: Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

State
Under way
Phase
Phase 2
People
189 taking part
Started
2 Apr 2021
Primary completion
3 Mar 2025
Arms
evorpacept (ALX148) + pembrolizumab
Results
None posted
  1. 19 Dec 2020: Trial registered
  2. 2 Apr 2021: Trial started

How the status changed

  1. 16 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.